319 related articles for article (PubMed ID: 35011320)
21. α-Synuclein aggregation nucleates through liquid-liquid phase separation.
Ray S; Singh N; Kumar R; Patel K; Pandey S; Datta D; Mahato J; Panigrahi R; Navalkar A; Mehra S; Gadhe L; Chatterjee D; Sawner AS; Maiti S; Bhatia S; Gerez JA; Chowdhury A; Kumar A; Padinhateeri R; Riek R; Krishnamoorthy G; Maji SK
Nat Chem; 2020 Aug; 12(8):705-716. PubMed ID: 32514159
[TBL] [Abstract][Full Text] [Related]
22. α-Synuclein phase separation and amyloid aggregation are modulated by C-terminal truncations.
Huang S; Mo X; Wang J; Ye X; Yu H; Liu Y
FEBS Lett; 2022 Jun; 596(11):1388-1400. PubMed ID: 35485974
[TBL] [Abstract][Full Text] [Related]
23. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
Chaari A; Eliezer D; Ladjimi M
Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
[TBL] [Abstract][Full Text] [Related]
24. O-GlcNAcylation inhibits the oligomerization of alpha-synuclein by declining intermolecular hydrogen bonds through a steric effect.
Wu K; Li D; Xiu P; Ji B; Diao J
Phys Biol; 2020 Dec; 18(1):016002. PubMed ID: 32906104
[TBL] [Abstract][Full Text] [Related]
25. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
26. Quinolinic Acid Amyloid-like Fibrillar Assemblies Seed α-Synuclein Aggregation.
Tavassoly O; Sade D; Bera S; Shaham-Niv S; Vocadlo DJ; Gazit E
J Mol Biol; 2018 Oct; 430(20):3847-3862. PubMed ID: 30098337
[TBL] [Abstract][Full Text] [Related]
27. Differential copper binding to alpha-synuclein and its disease-associated mutants affect the aggregation and amyloid formation.
Ranjan P; Ghosh D; Yarramala DS; Das S; Maji SK; Kumar A
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):365-374. PubMed ID: 27916677
[TBL] [Abstract][Full Text] [Related]
28. Modulating α-Synuclein Liquid-Liquid Phase Separation.
Sawner AS; Ray S; Yadav P; Mukherjee S; Panigrahi R; Poudyal M; Patel K; Ghosh D; Kummerant E; Kumar A; Riek R; Maji SK
Biochemistry; 2021 Dec; 60(48):3676-3696. PubMed ID: 34431665
[TBL] [Abstract][Full Text] [Related]
29. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
30. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
31. Conformational evolution of polymorphic amyloid assemblies.
Liang C; Hsieh MC; Li NX; Lynn DG
Curr Opin Struct Biol; 2018 Aug; 51():135-140. PubMed ID: 29729574
[TBL] [Abstract][Full Text] [Related]
32. Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution.
Li X; Dong C; Hoffmann M; Garen CR; Cortez LM; Petersen NO; Woodside MT
Sci Rep; 2019 Feb; 9(1):1734. PubMed ID: 30741954
[TBL] [Abstract][Full Text] [Related]
33. Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation.
Shaykhalishahi H; Gauhar A; Wördehoff MM; Grüning CS; Klein AN; Bannach O; Stoldt M; Willbold D; Härd T; Hoyer W
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8837-40. PubMed ID: 26119103
[TBL] [Abstract][Full Text] [Related]
34. Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization.
Roostaee A; Beaudoin S; Staskevicius A; Roucou X
Mol Neurodegener; 2013 Jan; 8():5. PubMed ID: 23339399
[TBL] [Abstract][Full Text] [Related]
35. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
36. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
Zaidi FK; Deep S
Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of α-synuclein aggregation within liquid condensates.
Dada ST; Toprakcioglu Z; Cali MP; Röntgen A; Hardenberg MC; Morris OM; Mrugalla LK; Knowles TPJ; Vendruscolo M
Nat Commun; 2024 May; 15(1):3835. PubMed ID: 38714700
[TBL] [Abstract][Full Text] [Related]
38. Interplay between α-synuclein amyloid formation and membrane structure.
O'Leary EI; Lee JC
Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):483-491. PubMed ID: 30287222
[TBL] [Abstract][Full Text] [Related]
39. Interactions between calcium and alpha-synuclein in neurodegeneration.
Rcom-H'cheo-Gauthier A; Goodwin J; Pountney DL
Biomolecules; 2014 Aug; 4(3):795-811. PubMed ID: 25256602
[TBL] [Abstract][Full Text] [Related]
40. Autophagy Modulation as a Treatment of Amyloid Diseases.
Mputhia Z; Hone E; Tripathi T; Sargeant T; Martins R; Bharadwaj P
Molecules; 2019 Sep; 24(18):. PubMed ID: 31527516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
